3023465-20-2
Chemical Structure
KRAS G12C-IN-78
- CAS No.: 3023465-20-2
- Formula:C37H31F4N7O3S
- Molecular Weight:729.75
InChIKey: RGYNSQCSLSKDGH-DVFHUXOUSA-N
SMILES: [H]C#CC1=C(C=CC2=CC(O)=CC(C3=C(C4=C(C(N5CCN(CC5)C(/C(F)=C/C6=NC=CS6)=O)=NC(OC[C@@]78CCCN7C[C@@H](C8)F)=N4)C=N3)F)=C21)F
Biological Activity: KRAS G12C-IN-78 is a selective SWII-binding KRASG12C dual inhibitor targeting both inactive and active states. KRAS G12C-IN-78 rapidly inhibits ERK1/2 phosphorylation, induces covalent adduct formation with endogenous KRASG12C, suppresses MAPK pathway gene expression, and inhibits cellular proliferation in KRASG12C mutant cells. KRAS G12C-IN-78 can be used for the research of KRASG12C mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KRAS G12C-IN-78 | KRAS G12C-IN-78 is a selective SWII-binding KRASG12C dual inhibitor targeting both inactive and active states. KRAS G12C-IN-78 rapidly inhibits ERK1/2 phosphorylation, induces covalent adduct formation with endogenous KRASG12C, suppresses MAPK pathway gene expression, and inhibits cellular proliferation in KRASG12C mutant cells. KRAS G12C-IN-78 can be used for the research of KRASG12C mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
